AstraZeneca will soon start a phase 3 trial of a subcutaneous version of its anti-CD19 T-cell engager.
ApexOnco Front Page
Recent articles
A son of glembatumumab vedotin has just started its phase 1 study.
PersonGen’s LV009 takes the industry tally of clinical-stage projects to 14.
Mocertatug rezetecan is starting its first western pivotal trials.
The holiday period included Genmab’s discontinuation of acasunlimab.
Nenocorilant features among the latest industry projects newly into phase 1.
A deal with Jacobio is worth $100m up front.
The private ADC company is being wound down.
